. home.aspx

home.aspx
   

Collaboration Is the X Factor in Making Precision Medicine a Success

November 11, 2019 / JOHN WISE

Last year, the FDA approved 59 new molecular entities for the US market, the highest number ever approved in a single year. A key driver of this record level of approvals is the explosive growth of precision medicine. Since 2015, at least a fifth of all new drug approvals each year have been precision therapies and in 2018 they accounted for nearly half (42 per cent). These numbers are a result of significant, sustained investment from pharma companies and highlight just how central this approach will be in life science R&D going forward. Yet investment into drug development isn’t the only factor that will determine the success of the precision medicine market.